-+ 0.00%
-+ 0.00%
-+ 0.00%
Cinda Biotech announced that the company Cindilizumab has received the first positive opinion from the European Medicines Agency's Human Medicines Committee. The CHMP recommended approval for marketing of cindirizumab in combination with chemotherapy for adult patients with advanced non-squamous non-small cell lung cancer. The recommendation is based on the results of the phase III ORIENT-11 study. Cindilizumab combined chemotherapy reduced the risk of disease progression or death by 52% and the risk of death by 35%. The European Commission is expected to make a final decision on the listing license within the next few months.
Share
Listen to the news
Cinda Biotech announced that the company Cindilizumab has received the first positive opinion from the European Medicines Agency's Human Medicines Committee. The CHMP recommended approval for marketing of cindirizumab in combination with chemotherapy for adult patients with advanced non-squamous non-small cell lung cancer. The recommendation is based on the results of the phase III ORIENT-11 study. Cindilizumab combined chemotherapy reduced the risk of disease progression or death by 52% and the risk of death by 35%. The European Commission is expected to make a final decision on the listing license within the next few months.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending